Siavoshian S, Simoneau C, Maugeais P, Marks L, Rodary L, Gardette J, Krempf M
Laboratoire de Nutrition Humaine, Hôpital G. and R. Laënnec, Nantes, France.
Clin Chim Acta. 1995 Dec 29;243(2):129-36. doi: 10.1016/0009-8981(95)06162-2.
Urinary excretion of mevalonate was reported to be correlated with endogenous cholesterol biosynthesis. A method is described whereby mevalonate (MVA) concentration in urine is determined by bench top gas chromatography-mass spectrometry after extraction as mevalonalactone (MVL) and conversion to mevalonolactone mono-TMS derivative. Within- and between-assay coefficients of variation were 4.02% and 8%, respectively. The mean concentration of MVA in 24-h urine collections from ten normolipidemic urinary subjects was 203 +/- 49.6 ng/ml (range: 44-576 ng/ml). Administration of 40 mg of Pravastatin (an HMG-CoA reductase inhibitor) significantly decreased (approximately 50%) the night concentration of MVA in five healthy volunteers. This assay could be useful for investigation of endogenous cholesterol synthesis rate in various dyslipidemias and in response to drug treatment.
据报道，甲羟戊酸的尿排泄与内源性胆固醇生物合成相关。本文描述了一种方法，通过该方法，尿中甲羟戊酸（MVA）浓度在提取为甲羟戊酸内酯（MVL）并转化为甲羟戊酸内酯单-TMS衍生物后，用台式气相色谱-质谱法测定。批内和批间变异系数分别为4.02%和8%。来自10名血脂正常的尿液样本的24小时尿液收集物中MVA的平均浓度为203±49.6 ng/ml（范围：44-576 ng/ml）。给予40 mg普伐他汀（一种HMG-CoA还原酶抑制剂）可使5名健康志愿者夜间MVA浓度显著降低（约50%）。该检测方法可用于研究各种血脂异常情况下内源性胆固醇合成速率以及药物治疗反应。
